1.Investigation on Clinical Pharmacist’s Work Status in West China Hospital of Sichuan University
Tiantian ZOU ; Naitong ZHOU ; Xuehua JIANG
China Pharmacy 1991;0(04):-
OBJECTIVE:To investigate the work status of clinical pharmacists in West China Hospital of Sichuan University and to provide rational suggestions for the development and improvement of clinical pharmacy. METHODS: The status of hospital clinical pharmacy and training of clinical pharmacy were studied by a questionnaire survey on 26 clinical pharmacists and an interview on 9 trainees majored in clinical pharmacy. RESULTS: The major tasks for hospital clinical pharmacists were to participate in clinical rounds, conduct pharmacy rounds alone, participate in patients’ treatment and outpatient pharmaceutical care, listen to case discussion, participate case consultation, coordinate with doctors to make medication plan, collect adverse drug reactions and give lecture among physicians etc. The pharmacists were welcome by most of the clinical departments. CONCLUSIONS: Clinical pharmacy in West Hospital of Sichuan University achieved a good beginning, but to achieve a further progress, the focus of clinical pharmacists’ work should be shifted to provide patient-centered pharmaceutical technical service, meanwhile, the support offered and the importance attached by the government as well as the efforts of clinical pharmacists are indispensible.
2.Study on the Assessment Indicator System of the Accessibility of Essential Medicines
Binchi LIAO ; Ming HU ; Naitong ZHOU ; Nan YANG ; Yifan HUANG
China Pharmacy 2016;27(18):2449-2451
OBJECTIVE:To explore the assessment indicators of the accessibility of essential medicines to comprehensively evaluate the accessibility of essential medicinesand its coverage of medicine supply security and service quality and the improve-ment of the implementation of the new Healthcare reform. METHODS:Retrieved from Chinese and English Literature and the World Health Organization(WHO),theoretical analysis was conducted for the covering the core elements of essential medicines to explore construction ideas and content of essential medicines evaluation index system with international suitability,index appropri-ateness and operability. RESULTS&CONCLUSIONS:A series of medicine policy evaluation guide established by WHO is current-ly the main basis of the accessibility of essential medicines evaluation around the world,however,there are certain limitations for these indicators.According to the concept put forward by WHO and the related organizations,the core elements of the accessibility of essential medicines include:availability,affordability,supply system,sustainable financing,medicine quality and appropriate use.
3.Investigation and Analysis of the Drug Accessibility Based on the Situation of Drug Use and Storage in Fami-lies in Chengdu
Jianlong YU ; Haiyao HU ; Shuang FENG ; Ming HU ; Naitong ZHOU
China Pharmacy 2016;27(21):2893-2897
OBJECTIVE:To provide reference for further comprehensive evaluation of the improvement of the accessibility of family medicines after the implementation of the new health care reform. METHODS:Sampled as 180 households from 2 urban ar-eas,2 counties and 2 rural areas in Chengdu,a questionnaire survey was adopted based on the WHO’s manual for the Household Survey to Measure Access and Use of Medicines to investigate the situation of drug use,storage and accessibility,and the results were statistically analyzed. RESULTS:Totally 180 questionnaires were sent out,179 were effectively received with effective recov-ery of 99.44%. In the terms of medicines taken for the acute illness,there were more than 60% rural households obtained drugs from the public health care facilities,while more than 60% counties households purchased drugs in public medical and health insti-tutions;in the terms of medicines taken for the chronic illness,the proportion of households reporting a chronic illness who did not take any medicines was low(3.80%);in terms of medicines storage,the proportion of households without reserve drugs was low (13.41%). In terms of drug accessibility,the proportions of respondents who agreed that the location and opening hours of their public healthcare facility were convenient were high;there was no situation for“patients did not take prescribed drugs because med-icines were not available at the healthcare facility and drug store”,while more than 95% respondents who agreed that drugs were available at their public health care facilities and drug stores;the essential medicines in the household use of chronic drugs in Chengdu accounted more than 60%;more than 85% can afford the drug costs,while the proportion of the monthly costs for acute illness and chronic illness in the total month costs was low;the health insurance coverage reached 90% in the survey households, but the proportions of households which could reimburse acute,chronic illness drug cost were lower(14.13% and 12.66%). CON-CLUSIONS:At present,the level of drug accessibility in Chengdu is high;the implementation of National Essential Medicines System has a positive effect on reducing the economic burden of chronic disease family. But there are shortcomings in the Medicare reimbursement levels and antibiotics use,it is suggested to take effective measures to solve it,such as exploring the stable and ef-fective medical insurance fund raising channels,improving the compensation level and the level of insurance reimbursement,formu-late and implement the corresponding antibacterial drugs supervision system and regulate the rational use of antibiotics in residents.
4.Clinical evaluation of Decitabine on the treatment of elderly patients with acute myeloid leukemia
Xueyun SHAN ; Mo ZHOU ; Xiaoli LI ; Naitong SUN
Clinical Medicine of China 2016;32(8):717-719
Objective To evaluate the clinical effect of Decitabine as the basis of the chemotherapy regimen on the treatment of elderly patients with acute myeloid leukemia( AML)?Methods The clinical data of elderly patients with AML admitted to the Third People ’ s Hospital of Yancheng from January 2013 to November 2015 were retrospective analyzed?The patients were divided into Decitabine group ( cases ) and the traditional group(19 cases) according to whether or not useed Decitabine,then evaluated the efficacy?Results The overall response rate( ORR) was 70?0% in 10 patients received decitabine,47?4% in 9 patents of the traditional group, and the difference was significant( P=0?03)?At the same time,the median survival time of the two groups was 44?87 months and 13?40 months respectively,the difference was statistically significant between the two groups (P=0?04)?There was no significant difference in the incidence of adverse reactions between the two groups ( granulocyte reduction, PLT reduction, fatigue, cardiovascular events, and respiratory tract infections ) ( P>0?05)?Conclusion The effect of Decitabine as the basis of the chemotherapy regimen on the treatment of AML is better,can prolong the survival time.
5.An Investigation of Pharmacy Administration Curriculum in Pharmacy Universities and Colleges in China
Ming HU ; Jian PU ; Xuehua JIANG ; Peng WU ; Naitong ZHOU
China Pharmacy 2005;0(22):-
OBJECTIVE:To provide suggestions for the improvement of curriculum system of Pharmacy Administration(Ph.A).METHODS:The basic information was collected by searching official website and the websites of universities and colleges,and the detailed data were collected through questionnaire survey.RESULTS:In the 111 universities and colleges investigated,a total of 51 curriculums(or 399 courses) related to Ph.A were set up.The main curriculums are pharmacy administration(210 courses),pharmaceutical marketing(61 courses),pharmacy laws and regulations(26 courses).In different universities and colleges,the credit hours,semester and property of Ph.A curriculums are different.CONCLUSIONS:The system of Ph.A curriculums has become more and more comprehensive,and the setup of each course suits the need of social needs.But the setup of curriculums of Ph.A in each university or college was far from systematical,and its structure remained to be optimized,and the structure of the teaching materials of Ph.A should be strengthened.
6.An Investigation of Pharmacy Administration Teacher Faculty in Pharmacy Universities/Colleges in China
Ming HU ; Jian PU ; Xuehua JIANG ; Peng WU ; Naitong ZHOU
China Pharmacy 2007;0(25):-
OBJECTIVE: To provide suggestion for the construction of teaching staff and the improvement of the discipline of Pharmacy Administration(Ph.A).METHODS: The basic information was collected by searching official website and the websites of universities and colleges etc,and a questionnaire survey was conducted among pharmacy univeristies or colleges by means of telephone interview or on-the-spot interview etc.RESULTS: A total of 108 pharmacy univeristies or colleges sent back the effective questionnaires.There were a total of 276 Ph.A teachers,including 142 male and 134 female;145 were full-time Ph.A and 131 were part-time teachers.There were only part-time teachers in 63 universities / colleges,of whom,91 were from other teaching or research department of the discipline of pharmacy,24 from party or government administration of school,9 from hospitals,4 from pharmaceutical manufacturing enterprises,and 3 from drug administration department.CONCLUSION: The resources of Ph.A teachers are various,and the access qualification is quite low.It isadvisable to strengthen the building of Ph.A faculty and improve the whole level of Ph.A teachers.
7.Changes of macrophage inflammatory protein of efficacy of zoledronic acid therapy of multiple mye-loma and determination in serum
Yunlong TANG ; Yan ZHOU ; Chunbin WANG ; Naitong SUN ; Xiaoyan YANG ; Yu SHAO ; Xueyun SHAN ; Mo ZHOU ; Weiwei SHENG
Journal of Chinese Physician 2016;(z1):9-11
Objective To study of zoledronic acid in the treatment of multiple myeloma bone dis-ease clinical effect and detection of serum macrophage inflammatory protein (MIP)changes of primary mye-loma (mm)in patients with serum macrophage inflammatory protein levels and multiple myeloma bone dis-ease curative effect.Methods 48 cases of multiple myeloma bone disease patients were treated with VTD regimen chemotherapy were randomly and equally divided into two groups,one group (group A)chemother-apy intermission applied zoledronic acid 4 mg per month 1 time,treatment 2 course of treatment,observa-tion of curative effect and adverse reaction,another group (B group)declined to azole phosphonic acid treatment.Results Group of pain Solution of 16 cases were markedly effective,effective in 4 cases,4 ca-ses were ineffective,efficiency 83.3%.B group bone pain relieved markedly effective in 12 cases,effective in 4 cases,8 cases were ineffective,have efficiency 66.7%.A compared to the B,the curative effect was obvious (P <0.05).By enzyme linked immunosorbent assay for the detection of the patients with a,levels of peripheral serum MIP-1a and MIP-1 beta B two groups before and after treatment.Conclusions zole-dronic acid in the treatment of multiple myeloma bone disease effectively,can significantly improve the qual-ity of life in patients with MM patients serum MIP-1a and MIP-1 beta level and multiple myeloma tumor bone disease curative effect is negative correlation,used for evaluating the effect The reference index.
8.An empirical study on the rational drug use in outpatients from different levels of health facilities in Sichuan Province
Xingyue ZHU ; Yan TIAN ; Naitong ZHOU ; Ming HU
Journal of Pharmaceutical Practice 2018;36(1):40-45
Objective To evaluate the current situation of rational drug use in medical facilities at all levels in Sichuan province by means of empirical research via WHO /INRUD selected drug use indicators SDUIs .Methods Six sample cities in Sichuan Province was extracted ,in which 1 to 3 tertiary hospitals ,1 to 3 secondary hospitals ,5 community health service cen-ters and 5 township hospitals were selected .Prescription indicators were indicated by collecting outpatient prescriptions from sample medical facilities which contained 30 prescriptions per month of every January ,April ,July and October from January 2012 to April 2015 .Results The average number of drugs was 3 .02 per prescription .The percentage of drug generic name used in prescription drugs was 90 .33% .The percentage of antimicrobial use was 40 .09% .The percentage of injections used was 14 .46% .The percentage of essential drugs used among prescription drugs was 83 .27% .The percentage of essential drugs used was 93 .05% .Average fee amount all prescriptions was 66 .04 yuan .Conclusion Some of the indicators was of good ra-tionality ,but there were still some unreasonable phenomena .
9. Clinical observation of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor for treatment of initial treatment elderly patients with acute myeloid leukemia
Mo ZHOU ; Yu SHAO ; Xueyun SHAN ; Chunbin WANG ; Pin WANG ; Naitong SUN
Journal of Leukemia & Lymphoma 2019;28(12):739-742
Objective:
To evaluate the efficacy and side effects of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the treatment of initial treatment elderly patients with acute myeloid leukemia (AML).
Methods:
Thirty-five elderly patients with early-stage AML (non-M3) who received pre-excitation chemotherapy in Yancheng Third People's Hospital from February 2015 to January 2019 were retrospectively analyzed. According to the different granulocyte colony-stimulating factor (G-CSF) in the chemotherapy regimen, 15 cases were in PEG-rhG-CSF group, 6 mg PEG-rhG-CSF was used alone on day 0 by subcutaneous injection; 20 cases were in recombinant human granulocyte colony-stimulating factor (rhG-CSF) group, 200 μg/m2 rhG-CSF was used per day from day 0 to day 13 by subcutaneous injection, rhG-CSF was suspended or continued according to the number of white blood cells. In addition, both groups were given priming regimen with cytarabine and arubicin, or cytarabine and harringtonine. The efficacy and adverse reactions of the two groups were compared.
Results:
In the PEG-rhG-CSF group, there were 5 cases of complete remission, 6 cases of partial remission, 4 cases of non-remission, and 11 cases were effective. In the rhG-CSF group, there were 8 cases of complete remission, 7 cases of partial remission, 5 cases of non-remission, and 15 cases were effective. There was no significant difference in the efficacy between the two groups (χ 2= 0.012,
10.Effect of ixazomib combination treatment therapies on multiple myeloma and the prognostic influencing factors
Yunlong TANG ; Yuqing MIAO ; Yifei CHEN ; Jiaqi LIU ; Yan ZHOU ; Naitong SUN ; Hongye LI
Cancer Research and Clinic 2023;35(12):910-914
Objective:To explore the efficacy of ixazomib combination treatment therapies for multiple myeloma (MM), and the influencing factors of prognosis.Methods:The clinical data of 80 MM patients admitted to Yancheng Third People's Hospital from January 2020 to January 2022 were retrospectively analyzed. All patients received 3 courses of ixazomib combination treatment therapies (28 d was 1 course). All combination treatment therapies included ID group (ixazomib + dexamethasone, 11 cases) and ID + immunomodulator group (ixazomib + dexamethasone + lenalidomide/thalidomide, 50 cases), ID + other chemotherapy drugs group (ixazzomib + dexamethasone + doxorubicin liposome/cyclophosphamide/bendamustine, 19 cases). The clinical efficacy of patients in different treatment regimens was compared, and the prognosis was followed up and recorded. The clinical characteristics between the survival and the dead patients were compared. Cox proportional risk model was used to make multivariate analysis of the overall survival of MM patients receiving ixazomib combination therapies.Results:The treatment was effective in 9 cases (81.82%) of the ID group, 32 cases (64.00%) of the ID + immunomodulator group, and 9 cases (47.37%) of the ID + other chemotherapy drugs group. There was no statistically significant difference in the effectiveness rate of 3 ixazomib combination regimens ( χ2 = 0.62, P = 0.432). All patients were followed up for 5 to 20 months, with an average follow-up time of (15±4) months. There were statistically significant differences in immunoglobulin type, Durie-Salmon stage, early treatment line and therapeutic efficacy between the survival group (49 cases) and the death group (31 cases) (all P < 0.05). Multivariate Cox regression analysis showed that the clinical effectiveness (effectiveness vs. ineffectiveness: OR = 0.242, 95% CI 0.103-0.567, P = 0.001) and the previous first-line treatment (the first-line vs. the other lines: OR = 0.577, 95% CI 0.452-0.736, P < 0.001) were independent protective factors for the overall survival of MM. Conclusions:The 3 ixazomib combination therapies have a certain efficacy in the treatment of MM; ID regimen has the best clinical efficacy and survival. The clinical effectiveness and the previous first-line treatment are independent protective factors for the survival of MM.